Edwards Lifesciences Corporation $EW Shares Sold by Paces Ferry Wealth Advisors LLC

Paces Ferry Wealth Advisors LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,428 shares of the medical research company’s stock after selling 142 shares during the period. Paces Ferry Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $538,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Vega Investment Solutions acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $26,000. SouthState Corp acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $27,000. Rossby Financial LCC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $29,000. Finally, Costello Asset Management INC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the transaction, the vice president owned 50,356 shares in the company, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $15,565,087. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,584 shares of company stock worth $1,897,762. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Up 0.5%

Shares of EW stock opened at $81.26 on Wednesday. The firm has a market cap of $47.71 billion, a P/E ratio of 11.69, a PEG ratio of 3.90 and a beta of 1.08. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm’s 50-day simple moving average is $77.87 and its 200-day simple moving average is $74.84.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the firm posted $0.70 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Wall Street Zen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Wells Fargo & Company raised their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Evercore ISI increased their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a report on Friday, July 25th. Finally, Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $85.90.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.